Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 safety and immunogenicity study of AdCLD-CoV19-1 COVID-19 vaccine
PACTR202210848418417Phase 2Not yet recruiting
- Sponsor
- Cellid Co., Ltd.
- Start
- Nov 2022
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2 trial of AdCLD-CoV19-1 OMI in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Cellid Co., Ltd. Primary endpoints: Immediate adverse events after each dose, Solicited local and systemic adverse events and 5 more. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
AdCLD-CoV19-1 OMI
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202210848418417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202210848418417.